PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Sacubitril/valsartan - Heart failure

PAD Profile : Sacubitril/valsartan - Heart failure Important

Keywords :
Sacubitril, CHF, valsartan, neprilysin inhibitor, angiotensin receptor antagonist
Brand Names Include :
Entresto
Important Information :
Do not co-administer with an ACEi or ARB due to risk of angioedema.

Traffic Light Status

Status 1 of 2.

Status :
Amber
Formulations :
  • Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
SA
Comments :
No comments returned.
Documents :

Status 2 of 2.

Status :
Non Formulary
Important
Formulations :
  • Granules
Important Information :
Only licensed for use in children.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
01 June 2016
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN recommends Sacubitril/Valsartan (Entresto®) for treating symptomatic chronic heart failure with reduced ejection fraction in line with NICE guidance (TA388 – April 2016) and will be considered as AMBER on the traffic light system. CCGs in conjunction with local Acute Trusts will make local implementation plans as required

Associated BNF Codes

02. Cardiovascular System
02.05.05. Renin-angiotensin system drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More